HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. It serves the biopharmaceutical companies, academic research centres, and molecular testing laboratories. Its proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Call scheduled for today, March 25, at 4:30pm ET Call scheduled for today, March 25, at 4:30pm ET

HTG Molecular Diagnostics Reports Full Year 2020 Results

HTG Molecular Diagnostics, Inc. (HTGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: HTG Molecular Diagnostics, Inc. (HTGM) Q4 Earnings Expected to Decline

TUCSON, Ariz., March 16, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will report its financial results for the year ended December 31, 2020 after the market close on Thursday, March 25, 2021. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.

HTG Molecular Diagnostics to Announce Year End 2020 Financial Results and Host Conference Call on Thursday, March 25

Biocept

Roche Holding AG (OTC: RHHBY) acquired GenMark Diagnostics, Inc (NASDAQ: GNMK) in a $1.8 billion deal on Monday, the same day Veracyte Inc (NASDAQ: VCYT) announced it completed the acquisition of Decipher Biosciences, Inc.  What Happened: With the cancer diagnostic market expected to grow to $261.34 billion by 2027 — more than double the $115.60 billion it was worth last year — big biotech companies have been on an acquisition spree to boost their portfolios and technology.

3 Cancer Diagnostic Stocks To Watch Following Roche's GenMark Buy

TUCSON, Ariz., Feb. 26, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it has completed its feasibility testing for a planned whole transcriptome panel using the HTG EdgeSeq technology, and has released a follow-on whole transcriptome product white paper (White Paper Two), regarding the performance of a prototype panel for multiple cancer indications compared to RNA sequencing (RNA-Seq). HTG is developing a whole transcriptome panel using the HTG EdgeSeq technology to measure approximately 20,000 mRNA targets, with a planned research use only launch in the third quarter of 2021.

HTG Concludes Feasibility Testing & Releases Second White Paper for its Planned Whole Transcriptome Panel Using HTG EdgeSeq Technology

Timothy Johnson to Retire from the Board; Ann Hanham, Ph.D. Remains Lead Independent Director Timothy Johnson to Retire from the Board; Ann Hanham, Ph.D. Remains Lead Independent Director

HTG Announces Board of Directors Transition

TUCSON, Ariz., Dec. 30, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has received notification of the issuance of Canadian patent number 2877729 for “Nuclease Protection Methods for Detection of Nucleotide Variants.”

HTG Expands Patent Portfolio with New Canadian Patent for its Nuclease Protection Methods for Detection of Nucleotide Variants

TUCSON, Ariz., Dec. 18, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has signed up the first collaborator in its recently announced Early Access Program for its prototype whole transcriptome panel. The Early Access Program is intended to allow select customers access to the panel in their laboratories or through services to be performed in our development laboratory prior to commercial launch of this product.

HTG Announces First Collaborator in Early Access Program for its Prototype Whole Transcriptome Panel

TUCSON, Ariz., Dec. 08, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has launched an Early Access Program for its whole transcriptome panel using the HTG EdgeSeq technology. The Early Access Program is intended to allow select customers access to the panel in their laboratories or through services to be performed in our development laboratory prior to commercial launch of this product.

HTG Announces an Early Access Program for its Prototype Whole Transcriptome Panel

TUCSON, Ariz., Nov. 23, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that as a result of its one-for-fifteen reverse stock split which became effective at 5:00 p.m. Eastern Time on November 20, 2020, its common stock will begin trading on a split-adjusted basis on The Nasdaq Capital Market (“Nasdaq”) effective with the open of the market today, Monday, November 23, 2020. HTG's common stock will continue to trade under the ticker symbol “HTGM.”

HTG Announces One-for-Fifteen Reverse Stock Split

HTG Molecular Diagnostics, Inc. (HTGM) CEO John Lubniewski on Q3 2020 Results - Earnings Call Transcript

Shares of HTG Molecular Diagnostics (NASDAQ:HTGM) decreased 3.2% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 53.33% year over year to ($0.07), which beat the estimate of ($0.08).

HTG Molecular Diagnostics: Q3 Earnings Insights

Call scheduled for today, November 10, at 4:30pm ET Call scheduled for today, November 10, at 4:30pm ET

HTG Molecular Diagnostics Reports Third Quarter 2020 Results

TUCSON, Ariz., Nov. 02, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the completion of proof of concept for a whole transcriptome panel using the HTG EdgeSeq technology, and release of a White Paper illustrating the feasibility and performance of this prototype panel relative to RNA sequencing (RNA-Seq). As previously discussed, HTG is developing a whole transcriptome panel utilizing the HTG EdgeSeq technology to measure approximately 20,000 mRNA targets, with a planned RUO launch in mid-2021.

HTG Demonstrates Technical Feasibility for a Whole Transcriptome Panel Using HTG EdgeSeq Technology

TUCSON, Ariz., Oct. 30, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will report its financial results for the third quarter ended September 30, 2020 after the market close on Tuesday, November 10, 2020. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.

HTG Molecular Diagnostics to Announce Third Quarter 2020 Financial Results and Host Conference Call on Tuesday, November 10

TUCSON, Ariz., Sept.  08, 2020  (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a diagnostic company whose mission is to advance precision medicine, today announced John Lubniewski, President and CEO of HTG, will present virtually at the H.C. Wainwright 22nd Annual Global Investment Conference and at the Cantor Fitzgerald Global Healthcare Conference. Details are as follows:

HTG Molecular Diagnostics to Present Corporate Overview at Fall Investor Conferences

TUCSON, Ariz., Aug.  18, 2020  (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the commercial release and immediate availability of HTG EdgeSeq Reveal version 3.0, adding additional applications and software functionalities.

HTG Introduces Oncology Applications and Expands Analytics Capabilities with Release of New Software Update

TUCSON, Ariz., Aug.  14, 2020  (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today provided an update regarding its patent infringement claims against BioSpyder Technologies, Inc (BioSpyder). On August 13, 2020, BioSpyder filed a lawsuit seeking a declaration that it does not infringe HTG’s U.S. Patent No. 8,741,564 (the ’564 patent). In several previous communications between the companies, HTG had asserted its claims that BioSpyder’s TempO-Seq® gene expression tool infringes the ‘564 patent. 

HTG Molecular Provides Update on Patent Infringement Claims Against BioSpyder

HTG Molecular Diagnostics' (HTGM) CEO John Lubniewski on Q2 2020 Results - Earnings Call Transcript

Shares of HTG Molecular Diagnostics (NASDAQ:HTGM) were flat in after-market trading after the company reported Q2 results.

HTG Molecular Diagnostics: Q2 Earnings Insights

HTG Molecular Diagnostics, Inc. (HTGM) delivered earnings and revenue surprises of 0.00% and 3.32%, respectively, for the quarter ended June 2020.

HTG Molecular Diagnostics, Inc. (HTGM) Reports Q2 Loss, Tops Revenue Estimates

Call scheduled for today, August 11, at 4:30pm ET Call scheduled for today, August 11, at 4:30pm ET

HTG Molecular Diagnostics Reports Second Quarter 2020 Results

TUCSON, Ariz., Aug.  10, 2020  (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the signing of a Commercialization and Distribution Agreement (Master Agreement) with QIAGEN Manchester Limited, a wholly owned subsidiary of QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) (QIAGEN).

HTG Molecular Diagnostics Announces New Commercialization and Distribution Agreement for Companion Diagnostics with QIAGEN

On Tuesday, August 11, HTG Molecular Diagnostics (NASDAQ: HTGM) will report its last quarter's earnings.

Earnings Preview: HTG Molecular Diagnostics

TUCSON, Ariz., Aug.  05, 2020  (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a diagnostic company whose mission is to advance precision medicine, today announced that it will report its financial results for the second quarter ended June 30, 2020 after the market close on Tuesday, August 11, 2020. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time.

News for HTG Molecular Diagnostics Stock (HTGM)